Results 71 to 80 of about 84,266 (263)

Prospective effect of linkers type on the anticancer activity of pemetrexed-monoclonal antibody (atezolizumab) conjugates [version 2; peer review: 2 approved, 1 approved with reservations]

F1000Research
Background Conventional chemotherapy results in severe toxic side effects due to affecting normal and cancer cells. The conjugation of chemotherapy with mAb will improve the chemotherapy selectivity towards cancer cells and at the same time will ...
Nidhal K. Maraie, Basma Talib Al-Sudani, Faten Q. Ibraheem, Ayad M.R. Raauf   +3 more
doaj   +1 more source

Data from Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody–Drug Conjugates in Pancreatic Cancer

, 2023
Shigehiro Tsujii, Satoshi Serada, Minoru Fujimoto, Sunao Uemura, Tsutomu Namikawa, Taisei Nomura, Ichiro Murakami, Kazuhiro Hanazaki, Tetsuji Naka   +8 more
openalex   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Table S2 from PCA062, a P-cadherin Targeting Antibody–Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin–expressing Malignancies

, 2023
Qing Sheng, Joseph A. D’Alessio, Daniel L. Menezes, Christopher Karim, Yan Tang, Angela Tam, Suzanna Clark, Ying Chi, Anu Connor, Keith G. Mansfield, Jean‐Michel Rondeau, Majid Ghoddusi, Felipe C. Geyer, Jane Gu, Margaret E. McLaughlin, Rick Newcombe, GiNell Elliot, William R. Tschantz, Sylvie Lehmann, Christie Fanton, Kathy D. Miller, Thomas Huber, Katherine G. Rendahl, Ursula Jeffry, Nancy Pryer, Emma Lees, Paul Kwon, Judith A. Abraham, Jason S. Damiano, Tinya J. Abrams   +29 more
openalex   +1 more source

Patient therapy outcome modeling in cancer organoids is improved by cancer‐associated fibroblasts and organoid assembly convolution

Molecular Oncology, EarlyView.
Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski, Liudmyla Dolinchuk, Michał Jerzak, Albert Gandurski, Tomasz Grochowski, Weronika Wojtyś, Maciej Zadrożny, Wojciech Kaźmierczak, Małgorzata Lenarcik, Marta Matejak‐Górska, Radosław Samsel, Tomasz Olesiński, Dawid Walerych   +12 more
wiley   +1 more source

Development of a Human IgG1 Monoclonal Antibody Targeting Transferrin Receptor 1 for Antitumor Drug Delivery

Antibodies
Background: Transferrin receptor protein 1 (TfR1) plays a central role in cellular iron uptake and is frequently overexpressed in malignant tumor cells, rendering it an attractive target for tumor-directed therapy and drug delivery.
Tingting Ji, Zhaoyun Zong, Ningyuan Gong, Minghui Yan, Shiyu Chen   +4 more
doaj   +1 more source

Supplementary Figure S5 from Nonclinical Development of Next-generation Site-specific HER2-targeting Antibody–drug Conjugate (ARX788) for Breast Cancer Treatment

, 2023
Prathap Nagaraja Shastri, Jingjing Zhu, Lillian Skidmore, Xuejun Liang, Yanping Ji, Yi Gu, Feng Tian, Sulan Yao, Gang Xia   +8 more
openalex   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1).

PLoS ONE, 2015
The humanized monoclonal antibody-drug conjugate trastuzumab emtansine (T-DM1, Kadcyla) has been approved by the U.S. FDA to treat human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.
Yuan-Chiang Chung, Jang-Fang Kuo, Wan-Chen Wei, King-Jen Chang, Wei-Ting Chao   +4 more
doaj   +1 more source

Supplementary Figure S3 from Nonclinical Development of Next-generation Site-specific HER2-targeting Antibody–drug Conjugate (ARX788) for Breast Cancer Treatment

, 2023
Prathap Nagaraja Shastri, Jingjing Zhu, Lillian Skidmore, Xuejun Liang, Yanping Ji, Yi Gu, Feng Tian, Sulan Yao, Gang Xia   +8 more
openalex   +1 more source